Women's health AI start-up Cercle secures $6m seed funding to expand data offering
Women's health AI start-up Cercle secures $6m seed funding to expand data offering
Cercle's AI-driven platform will provide insights for women's healthcare providers
AI platform Cercle has announced it has raised $6m in seed funding and will use the finances to expand its women’s health data and insights offering for healthcare providers.
The financing was led by Outsiders Fund, an early-stage venture capital firm supporting founders who disrupt overlooked, antiquated, and long-standing industries. Additional investments were made by FemHealth Ventures, CGHealth Ventures, and Rogue Women’s Fund. They join existing investors Sheryl Sandberg and Tom Bernthal’s SBVP fund, and a small number of individual angel investors.
Ashley Finch, Cercle’s COO said:
“Women’s healthcare is under researched, underfunded, and underserved.
“Our mission at Cercle is simple and clear: to leverage the power of AI to generate insights from women’s health data in order to drive efficiencies for providers, develop drugs faster, and improve care for patients. We are thrilled that this group of investors, led by Outsiders Fund, shares our passion for women’s healthcare and understands that transforming data into insights is a critical step to improve both business and clinical outcomes in women’s healthcare.”
Real-time, high-quality insights - with privacy protected
Healthcare is inundated with data – but 80% of the data is unstructured and extracting insights from that data is expensive and time consuming.
Cercle’s platform, the Cercle Biomedical Graph™, ingests and transforms de-identified healthcare data into real-time, high-quality insights that women's healthcare providers can use to run more efficient businesses and provide more personalised care. It promises to do this at speed and scale, and crucially without AI hallucinations.
Data privacy and security is also a priority for The Cercle Biomedical Graph and it is both HIPAA and GDPR compliant. Acting as a mediary between patient data records and LLMs, the Cercle Biomedical Graph removes all personal information and anonymizes data points and insights.
To date, Cercle has captured and analysed more than one billion data points from anonymised patients globally.
Expanding beyond fertility
Since its introduction in November 2023, the Cercle Biomedical Graph has been used by US Fertility, Boston IVF, and Eurofins Genoma, Cercle’s European-based distributor, among others, to drive efficiency for clinics and inform personalised treatments for fertility patients. The data has supported realistic timeline conversations and procedural options as well as setting expectations with patients.
Cercle will now use this seed funding to widen its application beyond the fertility market, expand its global footprint, and advance its LLM offerings.
Co-Founder and CEO Juan Carlos Riveiro is an experienced technologist and entrepreneur in AI and machine learning, and is working on connecting LLMs to high quality women's healthcare data.
This AI advancement will result in secure, accurate and real-time answers to questions asked by women's healthcare stakeholders. Cercle aims to broaden its customer base across the women’s healthcare ecosystem, reaching providers, payers, and pharma who work on reproductive health, menopause, women’s oncology, and other rare diseases that disproportionately impact women.
George Easley, Principal at Outsiders Fund said:
“Cercle is a truly exciting innovator at the intersection of AI and women’s healthcare.
“Cercle’s leadership team possesses a rare set of technical and operational skills that uniquely positions them to reimagine the uses of AI in and the data infrastructure of women’s healthcare. The company’s best-in-class infrastructure, LLM interface, and ML / AI models provide serious leverage to clinicians and healthcare operators alike. We are proud to lead this seed round and excited about what the future holds for Cercle.”
Dr. Eduardo Hariton, VP of Strategic Initiatives at US Fertility and Managing Director of the Innovation Fund said:
“Cercle’s unique AI platform has meaningfully enhanced both our business operations and clinical workflows.
“Analysing raw data for actionable insights is labor-intensive and costly. Cercle’s AI platform enables us to extract these insights more efficiently and at scale, leading to both better outcomes for our business and a better experience for our patients.”
The Cercle Biomedical Graph has not been evaluated by the U.S. Food and Drug Administration. It does not diagnose, treat, cure, or prevent any disease and is not classified as a medical device.